Eli Lilly (LLY) is targeting for 90%–100% skin clearance in psoriasis patients with its interleukin 17A (or IL-17A) antibody Taltz. The biologic reported lower revenues from $173 million in 4Q17 to $146 million in 1Q18 mainly due to wholesaler inventory changes. However, the demand for the drug increased from 4Q17 to 1Q18, which was reflected in a 30% quarter-over-quarter rise in new-to-brand prescriptions.
On December 1, 2017, the FDA approved Taltz as an injectable therapy for patients suffering from psoriatic arthritis. Taltz is competing with AbbVie’s (ABBV) Humira, Amgen’s (AMGN) Enbrel, and Novartis’ (NVS) Cosentyx in the psoriatic arthritis segment.
The above chart highlights Taltz’s revenue across the US and international markets. The graph also shows the growth trend in Taltz’s total prescriptions in the US since March 2016.
Eli Lilly expects readouts from the head-to-head trial comparing Taltz with Humira in late 2018. The company already completed one study evaluating Taltz in ankylosing spondylitis indication. The other study is expected to end in 2018.
IL-23 growth prospects
Eli Lilly is evaluating the anti-IL-23 drug, mirikizumab, in psoriasis and ulcerative colitis indications. The company has initiated the Phase 1 trial evaluating IL-23 CGRP bispecific antibody in the immunology segment.
Lartruvo’s growth prospects
Approved in combination with doxorubicin for patients suffering from certain types of soft tissue sarcoma indication in the US and Europe in late 2016, Latruvo reported revenues close to $64 million in 1Q18—52.3% growth year-over-year. While $43 million was earned by the drug in the US, the remaining $21 million was earned from international markets. At the end of February, the Latruvo and doxorubicin combination accounted for 38% of the share in the first-line metastatic soft tissue sarcoma market in the US.
Next, we’ll discuss Verzenio’s growth prospects.